January 24, 2022
1 min read
Save
FDA grants final approval for infantile spasm drug
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
The FDA has granted final approval to Zydus for Sabril, an anticonvulsant used to treat children aged 1 month to 2 years with infantile spasms.
Sabril (vigabatrin), which works by stopping the breakdown of a natural calming substance (GABA) in the brain, was approved in 500 mg tablet form. It can be used alongside other medications to treat seizure disorders.
The drug will be manufactured at the Zydus formulation facility in Ahmedabad, India.